Last Updated: 13 Nov 2024
Executive Summary
Twist Bioscience Corp (TWST) is a synthetic biology company that manufactures and sells synthetic DNA-based products. The company has a market capitalization of $2.77 billion and is headquartered in South San Francisco, California. TWST's latest stock price is $45.26.
Company Overview
Twist Bioscience was founded in 2013 and has since become a leader in the field of synthetic biology. The company's mission is to "make biology easier" by providing scientists with the tools they need to design, build, and test new DNA-based products. Twist Bioscience's products are used in a variety of applications, including drug discovery, diagnostics, and agriculture.
Fundamental Analysis
TWST's financial performance has been mixed in recent years. The company has reported losses in each of the past three fiscal years. However, revenue has grown steadily, and the company is expected to achieve profitability in the near future.
Technical Analysis
TWST's stock price has been in a downtrend since early 2022. The stock is currently trading below its 50-day and 200-day moving averages. The relative strength index (RSI) is also below 50, which indicates that the stock is oversold.
Short Term Outlook
The short-term outlook for TWST is mixed. The stock is currently trading at a discount to its fair value, and the company is expected to achieve profitability in the near future. However, the stock is in a downtrend and the RSI is below 50. This suggests that the stock could continue to decline in the short term.
Long Term Outlook
The long-term outlook for TWST is positive. The company is a leader in the field of synthetic biology, and its products are used in a variety of applications. The company is also expected to achieve profitability in the near future. This suggests that the stock could have significant upside potential in the long term.
Analyst Recommendations
Analysts are bullish on TWST. The average analyst rating is "Buy," and the average analyst target price is $53.09. This suggests that analysts believe that the stock is undervalued and has significant upside potential.
